New injection shows promise in battle against obesity

NCT ID NCT07114419

First seen Jan 05, 2026 · Last updated May 12, 2026 · Updated 27 times

Summary

This study tests an investigational drug called efsubaglutide alfa (YN-011) to see if it helps people with overweight or obesity lose weight safely. About 200 adults aged 18 to 75 will receive weekly injections of the drug or a placebo for 22 weeks. The main goal is to measure how much weight they lose and how many achieve at least 5%, 10%, or 15% weight loss.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Canopy Clinical Altona North

    RECRUITING

    North Altona, Australia

    Contact

  • Canopy Clinical Northern Beaches

    RECRUITING

    Brookvale, Australia

    Contact

  • Canopy Clinical Sutherland Shire

    RECRUITING

    Miranda, Australia

    Contact

  • Canopy Clinical Wollongong

    RECRUITING

    Wollongong, Australia

    Contact

  • Fusion Clinical Research

    RECRUITING

    Norwood, Australia

    Contact

Conditions

Explore the condition pages connected to this study.